Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement

Next Previous
Trial Profile

A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms RECOVERY
  • Sponsors Janssen Research & Development

Most Recent Events

  • 30 Oct 2017 Status changed from active, no longer recruiting to discontinued.
  • 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
  • 19 Apr 2017 Planned End Date changed from 13 Apr 2018 to 15 Jan 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top